BPC – 157 (10 MG)

Description

BPC 157 peptide benefits

Synthetic BPC 157 peptide, a pentadecane peptide that comprises 15 amino acids confined from the much larger BPC protein, has been observed to retain a number of healing properties of its parent molecule.
Research into BPC-157 shows direct correlations with:

• Increases collagen production
• Decreases inflammation
• Heals muscle tears and ligament damage
• Regenerates muscle and ligament tissue at a faster than average rate
• May decrease pain in damaged areas of the body
• Helps protect digestive function and counter the damaging effects that NSAID’s like Ibuprofen and Advil can have on the lining of the gut
• Increases growth hormone receptors
• Contains significant antioxidant qualities
• Wound healing
• Blood vessel growth
• Nitric oxide generation
• Immune system function
• Gene expression
• Hormone regulation (particularly in the gastrointestinal nervous system)

In addition to this, BPC-157 also appears to support the durability of cells at the sites of wounds. Actually, research showed that injured cells actively responded to the potent peptide by regenerating and healing themselves at a faster rate than in general. Hence, it is a no brainer that BPC-157 offers a wide range of benefits, including alleviates aches, pain and arthritis.

BPC-157 Peptide and Wound Healing Research

The usual work of BPC 157 peptide in the GI tract is to preserve the rectitude of the mucosal barrier that safeguards underlying tissues from the adverse actions of gastric acid, bile, and other compounds required for digestion and absorption of nutrients from food.  At least part of this function is mediated through the usage of fibroblasts.  BPC-157 has a dose-dependent effect on the spread of fibroblasts, causing the cells to both escalate and migrate faster[1].  Fibroblasts are integral to wound healing as they are the cells responsible for laying down extracellular matrix proteins like collagen, fibrin, elastin, and more.

Vascular Growth and Collateralization

BPC-157 is a potent angiogenic factor and as a result it increases the rate at which endothelial cells (the cells that line blood vessels) proliferate and grow[1]–[3]. Research in rats are the evidence that suggests the role of the peptide in increasing the rate of collateral blood vessel growth in the setting of ischemia[4]. While this effect has been mainly observed in the GI tract, there is evidence for similar benefit in cardiovascular, neurological, and muscle tissues. This suggests that BPC-157 may be used as both a therapy in the setting of stroke and heart attack as well as a probative peptide for promoting healing after ischemic injury[5], [6]. Studies in chicken embryos suggest that at least part of the mechanism by which BPC-157 alleviates vascular growth is via stimulating VEGFR2, a cell surface receptor active in the nitric oxide signaling pathway[4], [7], [8]. VEGFR2 plays a vital role in endothelial cell growth, proliferation, and longevity. Cell culture research has efficiently shown vascular “running” secondary to BPC-157 administration. Vascular running can be defined as the process by which vessels grow toward injured area or around an area of vascular occlusion to restart blood flow to distal tissue and protect cell function[9]. If you are looking for bpc 157 for sale to use in your research, you might be amazed at the fact that this function of BPC-157 10 mg peptide may make it possible to develop an effective oral treatment for slow-growing arterial occlusions as seen in atherosclerotic heart disease.  This area of research may one day render unrequired surgical interventions such as stenting, coronary artery bypass grafting, and more.  

BPC-157 and Tendon Healing

Given its roles in fibroblast recruitment and blood vessel growth, it should come as no brainer that BPC-157 has shown positive results in animal models of tendon, ligament, bone, and other connective tissue injuries.  As it is a fact that tendon and ligament injuries are slow to heal largely due to poor blood supply to these tissues.  Poor blood supply slows the rate at which fibroblasts and other wound-healing cells can reach the injured area and, ultimately, restricts the overall repair progress that can take place. Research involving rat tendons has shown that BPC-157 promotes collateralization and boosts fibroblast density substantially to promote muscle healing.  This research indicates that BPC-157 is more effective than bFGF, EFG, and VGF hormones in promoting healing in these tissues[10].  Experiments using FITC-phalloidin staining have revealed that BPC-157 is a competitive stimulator of F-actin formation in fibroblasts.  F-actin is critical to cell structure and function, playing an important role in cell migration. Analysis via western blotting indicates that BPC-157 increases phosphorylation of paxillin and FAK proteins, which are critical proteins in the cell migration pathway[12].

BPC-157 Antioxidant Properties

Research in rats has given us the evidence that BPC-157 can neutralize certain oxidative stress markers like nitric oxide and malondialdehyde (MDA)[3]. This makes BPC-157 a powerful antioxidant, a property of the peptide that is further supported by research showing that it can decrease the production of reactive oxygen species in the GI tract. Research investigating whether modified Lactococcus lactis bacteria can deliver BPC-157 to the gastrointestinal system shows that the bacteria increases levels of the peptide dramatically in cell culture[13].

Article Author

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Scientific Journal Author

Predrag Sikiric, lead author of “Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing”, and co-author of “Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions,” is a Professor of Medical Department at University of Zagreb. Predrag Sikiric is listed in [9] and [16] under the referenced citations.  Predrag Sikiric is being referenced as one of the leading scientists involved in the research and development of BPC-157. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between PeptidesforSale.com and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.

Referenced Citations

[1] T. Huang et al., “Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro,” Drug Des. Devel. Ther., vol. 9, pp. 2485–2499, 2015. [PubMed]

[2] D. Drmic et al., “Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine,” World J. Gastroenterol., vol. 24,48, pp. 5462–5476, Dec. 2018. [PubMed]

[3] F. Amic et al., “Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine,” World J. Gastroenterol., vol. 24, no. 47, pp. 5366–5378, Dec. 2018. [PubMed]

[4] A. Duzel et al., “Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights,” World J. Gastroenterol., vol. 23,48, pp. 8465–8488, Dec. 2017. [PubMed]

[5] J. Vukojević et al., “Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157,” Vascul. Pharmacol., vol. 106, pp. 54–66, 2018. [PubMed]

[6] D. Drmic et al., “Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME,” World J. Gastroenterol., vol. 23, no. 29, pp. 5304–5312, Aug. 2017. [PubMed]

[7] M.-J. Hsieh et al., “Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation,” J. Mol. Med. Berl. Ger., vol. 95, no. 3, pp. 323–333, 2017. [PubMed]

[8] Z. Grabarevic et al., “The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks,” J. Physiol. Paris, vol. 91, no. 3–5, pp. 139–149, Oct. 1997. [PubMed]

[9] P. Sikiric et al., “Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing,” Curr. Pharm. Des., vol. 24, no. 18, pp. 1990–2001, 2018. [PubMed]

[10] S. Seiwerth et al., “BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing,” Curr. Pharm. Des., vol. 24, no. 18, pp. 1972–1989, 2018. [PubMed]

[11] C.-H. Chang, W.-C. Tsai, M.-S. Lin, Y.-H. Hsu, and J.-H. S. Pang, “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration,” J. Appl. Physiol., vol. 110, no. 3, pp. 774–780, Oct. 2010. [PubMed]

[12] Y.-L. Hu et al., “FAK and paxillin dynamics at focal adhesions in the protrusions of migrating cells,” Sci. Rep., vol. 4, p. 6024, Aug. 2014. [Nature.com]

[13] K. Škrlec et al., “Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities,” Appl. Microbiol. Biotechnol., vol. 102, 23, pp. 10103–10117, Dec. 2018. [PubMed]

[14] D. Strinic et al., “BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats,” Life Sci., vol. 186, pp. 66–79, Oct. 2017. [PubMed]

[15] N. Jelovac et al., “Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats,” Eur. J. Pharmacol., vol. 379, no. 1, pp. 19–31, Aug. 1999. [PubMed]

[16] I. Tlak Gajger, J. Ribarić, M. Smodiš Škerl, J. Vlainić, and P. Sikirić, “Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions,” J. Vet. Pharmacol. Ther., vol. 41, no. 4, pp. 614–621, Aug. 2018. [PubMed]